A detailed history of Private Advisor Group, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Private Advisor Group, LLC holds 11,345 shares of ARWR stock, worth $215,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,345
Previous 11,372 0.24%
Holding current value
$215,101
Previous $295,000 25.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$19.36 - $29.54 $522 - $797
-27 Reduced 0.24%
11,345 $219,000
Q2 2024

Aug 05, 2024

BUY
$21.87 - $28.24 $546 - $706
25 Added 0.22%
11,372 $295,000
Q1 2024

Apr 30, 2024

SELL
$27.21 - $39.48 $13,169 - $19,108
-484 Reduced 4.09%
11,347 $324,000
Q4 2023

Feb 06, 2024

BUY
$21.2 - $31.03 $1,038 - $1,520
49 Added 0.42%
11,831 $362,000
Q2 2023

Aug 09, 2023

SELL
$25.16 - $41.38 $327 - $537
-13 Reduced 0.11%
11,782 $420,000
Q3 2022

Oct 14, 2022

BUY
$29.63 - $48.31 $9,274 - $15,121
313 Added 2.73%
11,795 $390,000
Q2 2022

Jul 13, 2022

SELL
$27.79 - $50.61 $1,722 - $3,137
-62 Reduced 0.54%
11,482 $404,000
Q1 2022

May 12, 2022

SELL
$39.62 - $69.97 $515 - $909
-13 Reduced 0.11%
11,544 $531,000
Q4 2021

Feb 10, 2022

BUY
$58.09 - $82.51 $6,564 - $9,323
113 Added 0.99%
11,557 $766,000
Q3 2021

Oct 14, 2021

BUY
$58.38 - $84.96 $668,100 - $972,282
11,444 New
11,444 $714,000
Q3 2020

Nov 02, 2020

SELL
$33.21 - $51.27 $7,605 - $11,740
-229 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$26.12 - $43.27 $5,981 - $9,908
229 New
229 $10,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.